A federal court has upheld a previous decision from March, asserting that Tolmar Inc. did not successfully demonstrate the invalidity of a patent related to Janssen Pharmaceuticals’ popular schizophrenia medication, Invega Sustenna. Tolmar’s contention was based on claims that the patent was obvious, but the court found these arguments unpersuasive. This decision maintains the validity of the patent, a significant victory for Johnson & Johnson, Janssen’s parent company. Further details on the case and its implications can be accessed here.